A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer

This is a single-center, single-arm, open investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of resectable pancreatic cancer.

Trial Details

NCT ID
NCT06758544
Phase
PHASE1 / PHASE2
Sponsor
Guangdong Provincial People's Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Oncolytic virus VRT106
  • Chemotherapy
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Subject voluntarily agrees to participate in this study and signs an Institutional Review Board -approved informed consent prior to performing any …
  • Males and females at 18-75 years of age, inclusive, at the Screening Visit.
  • Have a clinical diagnosis of pancreatic cancer.
  • An Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →